Blog
882 Articles
Trying a New Type of Treatment to Stop Advanced Pancreatic Cancer
Researchers test the chemotherapy combination of AM0010 and FOLFOX as a second-line therapy for people with metastatic pancreatic cancer.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Testing the Safety of a New Chemotherapy and Radiation Combination
A clinical trial tests the effectiveness of adding PEGPH20 to standard chemotherapy and radiation in patients with locally advanced pancreatic cancer.
Predicting Effective Therapy in Pancreatic Cancer
Dr. Kenneth Yu is leading a clinical trial that looks at a pancreatic cancer patient’s pharmacogenomic profile, to see which chemotherapy works better.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Targeted Therapy for Pancreatic Cancer
Dr. Margaret Tempero outlines the work being done in the area of targeted therapy for pancreatic cancer, specifically the testing of ibrutinib.
Adding a New Drug to Standard Treatment for Metastatic Pancreatic Cancer
A clinical trial tests the effectiveness of napabucasin, a drug that affects the signaling pathways of cancer stem cells.
New Crowdsourcing Platform Connects Pancreatic Cancer Patients to the Latest Studies
Dr. Allyson Ocean, a founder of Let’s Win, has a short video that explains how the website uses crowdsourcing of information for pancreatic cancer patients.
Stereotactic Body Radiation Therapy (SBRT) for Select Pancreatic Cancer Patients
Stereotactic body radiation therapy (SBRT) is increasingly being used to treat locally advanced pancreatic cancer, and make it surgically removable.
Focusing on a Drug that Treats Specific Tumor Mutations
A clinical trial tests a signal-inhibiting drug for lung cancers with specific genetic mutations on gastrointestinal cancers with the same tumor mutations.